Earlier pieces referenced "selective enforcement" and "only 39 authorized products" in the US market. This one drills a layer deeper — laying out the cost and volume figures behind PMTA review shows that the current shape of the US vape market is essentially the inevitable output of an economics problem, not simply a matter of enforcement attitude.
A staggeringly lopsided ratio
FDA's own data shows: the vape category has received more than 6 million PMTA applications, with only about 45 ultimately authorized. That approval rate isn't just "strict review" — it's a gap wide enough that the vast majority of applications were essentially never going to clear the bar from the start.
For comparison, in the 2016 Deeming Rule, the FDA itself estimated PMTA cost per ENDS device at $28,566 to $2,595,224, averaging $466,563; per e-liquid formulation, $12,112 to $398,324, averaging $131,643. That's a 2016-era estimate — multiple industry reports since indicate real-world costs commonly run higher.
Why the cost runs this high
A PMTA isn't a form-filling exercise — it requires a complete scientific case demonstrating that authorizing the product is net-positive for public health across the population. In practice, that usually means submitting:
- A full chemical composition analysis of the product
- Toxicology testing data
- User behavior research (particularly around youth uptake risk)
- Comparative risk studies against traditional cigarettes
This bar looks closer to a pharmaceutical approval standard than an ordinary consumer-product compliance check. For a category like disposable vapes — where product iteration cycles are measured in months — a device can easily be superseded by the next generation before a review decision even comes back. That's a big part of why most manufacturers choose to sell while filing rather than wait to sell until approved.
Who's actually gotten through: a list with a pattern
Scanning the FDA's public Marketing Granted Order records reveals a common thread among authorized products — most belong to well-capitalized large companies, and a disproportionate share are nicotine pouches, not traditional vape devices:
- ZYN (all 20 SKUs, authorized January 2025)
- on! PLUS (6 SKUs, authorized December 2025)
- JUUL2 (authorized August 2026)
- Swedish Match's ZYN ULTRA (authorized August 2026)
Only two nicotine pouch brands — ZYN and on! PLUS — hold authorization across 26 SKUs total. Well-known brands still in the queue, including VELO, Rogue, Lucy, and FRE, have been waiting nearly six years since filing, with no authorization yet. This list itself says something: surviving the PMTA process largely requires the capital and legal resources to absorb years of waiting cost — a bar mostly cleared by top-tier incumbents.
The practical takeaway for buyers
This underlying economics directly shapes the real-world status of any product you're sourcing for the US market:
- Small and emerging brands' products are essentially never going to secure PMTA authorization — not because the product itself is flawed, but because the cost and timeline of the process are simply unrealistic for most manufacturers
- "PMTA filed" and "PMTA authorized" can be years apart — or never converge at all — treat this as a supplier-screening dimension, not a binary "did they file or not" check
- If a supplier claims their product's "PMTA is under review," it's worth asking when it was filed. An application pending 3-4+ years with no decision is unlikely to resolve soon — plan channels around the reality of long-term grey-area status rather than an optimistic expectation of imminent compliance
(General information only, not legal advice — consult a lawyer familiar with FDA compliance before making business decisions.)